Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. – UroToday
|
Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
UroToday This had led to a revisitation of immunotherapy in urothelial cancer, as well as the genesis of trials using novel immunotherapeutic agents. This review focuses on immunotherapy in NMIBC, both on its own and as a potential treatment in combination with RT. |
